Medicare’s controversial draft decision – released on January 11th of this year – to restrict coverage of Aduhelm to beneficiaries who enroll in post-marketing clinical trials may be the only feasible option left for the product. Such a policy is called coverage with evidence development.
Aduhelm’s Paltry $1 Million In Q4 Sales Indicates CMS’s Coverage With Evidence Development May Be Biogen’s Only Chance At Salvaging Something From The Product
